United States Army Medical Research Institute of Infectious Diseases

Maxwell Biosciences Enters CRADA with USAMRIID to Test Claromer Compounds as Potential Therapeutics for Viral Pathogens, Including Hemorrhagic Fever Ebola Viral Disease, and Other Biodefense Pathogens

Retrieved on: 
Wednesday, October 25, 2023
CRADA, Ageing, Cooperative research and development agreement, Therapy, Maxwell, United States Army Medical Research and Development Command, Biological warfare, U.S. Army Public Health Center, United States Army Medical Research Institute of Infectious Diseases, Development, USAMRIID, McClure, Infection, Peptide, Vaccine

USAMRIID to study antiviral activity of Claromer technology against national priority biodefense threats

Key Points: 
  • Part of the U.S. Army Medical Research and Development Command, USAMRIID is the U.S Army's premier institution and facility for defensive research into countermeasures against biological warfare, located on Fort Detrick, Maryland.
  • "As a military veteran, I'm proud to lead a team that tirelessly seeks to fill critical unmet needs for more effective therapeutics against the worst global pathogens."
  • "Our Claromer technology has the potential to replace almost all antibiotics, antifungals and antivirals - and it may help with healthy aging as well," continued McClure.
  • "Signing this CRADA with USAMRIID, the world's preeminent biodefense research organization, is another validation of Maxwell's Claromer technology's potential as an important, disruptive platform technology."

PureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome

Retrieved on: 
Tuesday, August 1, 2023
Mental Health, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, PRTC, LSE, Defense Health Agency, University of California, Davis, Tremor, Anxiety, University, Therapy, U.S. Department of Defense Strategy for Operating in Cyberspace, United States Department of Defense, Ageing, PureTech Health, FMR1, Research, Medicine, Development director, Element, Veteran, CNS, Dementia, Trial of the century, Science, Assistant, Intellectual disability, FXS, Fragile X syndrome, UC, Patient, Department of Defense Serum Repository, United States Army Medical Research and Development Command, Spectrum, United States Army Medical Research Institute of Infectious Diseases, MIND Institute, FXTAS, Office of the Assistant Secretary for Health, Assistant Secretary of Defense for Health Affairs, Glyph, Cannabidiol, Safety, Allopregnanolone, Pharmaceutical industry, Vaccine, Defense, Fragile

The funds will support a Phase 2 trial of LYT-300 in collaboration with the University of California, Davis (UC Davis).

Key Points: 
  • The funds will support a Phase 2 trial of LYT-300 in collaboration with the University of California, Davis (UC Davis).
  • Both conditions are the result of repeated elements in the Fragile X Messenger Ribonucleoprotein Gene 1 (FMR1) gene.
  • Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.
  • In addition to LYT-300, which is being advanced in three indications, PureTech is progressing multiple CNS-focused programs derived from its Glyph platform.

EQS-News: Rentschler Biopharma SE : Dr. Dominik Kugelstadt joins as Head of Clinical and Commercial Manufacturing, Laupheim

Retrieved on: 
Wednesday, July 12, 2023
Head, Antibody, Heidelberg University, Teaching hospital, CDMO, United States Army Medical Research Institute of Infectious Diseases, Patient, Biology, Commercial, Infection, Medical device, Fine chemical, Sanofi

Rentschler Biopharma SE : Dr. Dominik Kugelstadt joins as Head of Clinical and Commercial Manufacturing, Laupheim

Key Points: 
  • Rentschler Biopharma SE : Dr. Dominik Kugelstadt joins as Head of Clinical and Commercial Manufacturing, Laupheim
    The issuer is solely responsible for the content of this announcement.
  • Dr. Dominik Kugelstadt joins Rentschler Biopharma as Head of Clinical and Commercial Manufacturing, Laupheim
    Laupheim, Germany, July 12, 2023 – Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced the appointment of Dr. Dominik Kugelstadt as Head of Clinical and Commercial Manufacturing, Laupheim, effective July 1, 2023.
  • In this position, Dr. Kugelstadt is responsible for all areas of production and reports to Laupheim’s Site Head as a member of the Laupheim Site Leadership Team.
  • “I am very pleased to welcome Dominik to our team,” said Christiane Bardroff, COO of Rentschler Biopharma.

Noted Vaccine Researcher Thomas P. Monath Awarded Sabin’s Gold Medal; Cameroon Physician Sangwe Clovis Nchinjoh Receives Rising Star Award

Retrieved on: 
Tuesday, June 6, 2023
Vaccine, Arbovirus, Gold medal, United States Army Medical Research Institute of Infectious Diseases, Private sector, Sabin Vaccine Institute, Gold, USAMRIID, Vaccination, Virology, Public, Rising Star, Infection, Yellow fever, Smallpox, DRS, Viral, Research, CDC, Fever Dream, Division, Finan, United States Department of the Army, Korea Disease Control and Prevention Agency, Lassa fever, Health, Knowledge, Viral encephalitis, Science, R, System, MPH, Immunization, MD

WASHINGTON, June 06, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today awarded the 30th Albert B. Sabin Gold Medal Award to Thomas P. Monath, MD, and its Rising Star Award to Sangwe Clovis Nchinjoh, MD, MPH, in a ceremony at Washington D.C.’s National Academy of Sciences building.

Key Points: 
  • WASHINGTON, June 06, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today awarded the 30th Albert B. Sabin Gold Medal Award to Thomas P. Monath, MD, and its Rising Star Award to Sangwe Clovis Nchinjoh, MD, MPH, in a ceremony at Washington D.C.’s National Academy of Sciences building.
  • Past award recipients include leaders of vaccinology and vaccine advocacy such as Drs.
  • Sabin’s Rising Star is awarded to encourage and recognize the next generation of vaccine and immunization leaders.
  • “With his focus on strengthening immunization and health services among some of our most neglected communities, Dr. Nchinjoh exemplifies the spirit behind the Rising Star award,” says Finan.

SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies

Retrieved on: 
Friday, May 12, 2023
SAB, United States Army Medical Research Institute of Infectious Diseases, Antigen, Plague, Partnership, SARS-CoV-2, Public, Infection, Phagocytosis, Mutation, Yersinia pestis, Immunotherapy, Pneumonic plague, Bubonic plague, F1, Viral, Mouse, Search for the Higgs boson, LcrV, Vaccine, MD, Antibody, TC

SIOUX FALLS, S.D., May 12, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin (hIgG) antibodies, also known as fully-human polyclonal antibodies, without the need for human donors, today announced the publication of nonclinical data in the medical journal Antibodies. The data are from a study conducted in collaboration with the United States Army Medical Research Institute of Infectious Diseases (USAMRID) highlighting that fully-human immunoglobulins derived from Tc bovines can protect mice from Yersinia pestis, a Tier 1 select bacterial biothreat agent that can rapidly cause fatal infections and is associated with pneumonic plague as well as bubonic plague.

Key Points: 
  • The article, “ Polyclonal antibodies derived from transchromosomic bovines vaccinated with the recombinant F1-V vaccine increase bacterial opsonization in vitro and protect mice from pneumonic plague ,” was published online in the 10th anniversary special issue of Antibodies.
  • Y. pestis is a major biothreat due to its capacity for aerosol dissemination and its highly contagious nature in the pneumonic form.
  • “These promising nonclinical data generated in partnership with USAMRID offer evidence that SAB-183 may provide broad coverage against plague and other mutating infections,” said Tom Luke, MD, Head of Research for SAB Biotherapeutics.
  • This publication marks the first study data that have been announced for SAB-183.

PharmaJet Announces U.S. Government Award Expansion to Clinically Assess a DNA Vaccine Combined with its Systems

Retrieved on: 
Tuesday, April 18, 2023
Biotechnology, Medical Devices, Infectious Diseases, Health, Pharmaceutical, Stratis, Injection, United States Army Medical Research Institute of Infectious Diseases, DNA, Human, Partnership, Use, Alphavirus, U.S. Department of Defense Strategy for Operating in Cyberspace, USAMRIID, Licensure, Venezuelan equine encephalitis virus, DTRA, ID, Epidemic, Investigational New Drug, PDS, CGMP, Mortality, NHP, Defense Threat Reduction Agency, Encephalitis, IND, Infection, Pharmaceutical industry, Vaccine

The expansion award, worth over $4 million, will be used to further advance the clinical assessment of its Venezuelan Equine Encephalitis Virus (VEEV) DNA candidate vaccine in combination with either Tropis Intradermal (ID) or Stratis Intramuscular (IM) Systems.

Key Points: 
  • The expansion award, worth over $4 million, will be used to further advance the clinical assessment of its Venezuelan Equine Encephalitis Virus (VEEV) DNA candidate vaccine in combination with either Tropis Intradermal (ID) or Stratis Intramuscular (IM) Systems.
  • Venezuelan Equine Encephalitis Virus is an alphavirus that causes encephalitis and potential mortality in infected humans and equines.
  • It is listed as a potential biothreat agent with no approved human vaccine or therapeutic currently available.
  • PharmaJet is working with a contract manufacturer to produce the cGMP VEEV plasmid DNA vaccine and is preparing the Investigational New Drug (IND) application.

AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease

Retrieved on: 
Thursday, March 16, 2023
Research, Conference, United States Army Medical Research Institute of Infectious Diseases, Mortality, Tropical disease, NYSE, RNA, Viral, Environmental science, Manuscript, University of Cagliari, International Conference on Emerging Infectious Diseases, ICAR, Ebola, Laboratory, AIM, Human, TLR3, PAMP, COVID-19, FDA, Disease, European Medicines Agency, Antiviral Research, EBOV, Doctor of Philosophy, Orphan drug, EVD, Investigational New Drug, Cancer, DSM-IV codes, Therapy, University, Vaccine, Pharmaceutical industry, Central Africa, Rintatolimod

Highlights of the recently published Ampligen data that was presented include:

Key Points: 
  • Highlights of the recently published Ampligen data that was presented include:
    As a TLR3 agonist, Ampligen induces and enhances innate immunological responses to EBOV infection.
  • AIM CEO Thomas K. Equels commented, “In vivo pre-clinical analysis shows that Ampligen has potential as both a prophylactic and an early-onset therapeutic in Ebola virus disease.
  • Animal studies with Ampligen at the United States Army Medical Research Institute of Infectious Diseases Biosafety Level 4 laboratories demonstrated 100% protective survival, as compared to 100% mortality in Ebola virus disease.
  • Ultimately, the Company's goal is to seek a Tropical Disease Priority Review Voucher for new drug applications associated with these indications.

Vivacelle Bio’s VBI-S Phase IIa Clinical Trial Meets Primary and Secondary Endpoints for Treating Hypovolemia in Septic Shock Patients

Retrieved on: 
Thursday, February 9, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Septic shock, OTA, Hypovolemia, Physician, United States Army Medical Research and Development Command, United States Army Medical Research Institute of Infectious Diseases, ECMO, Extracorporeal membrane oxygenation, Biomedical technology, Probability, Patient, Clinical trial, Shock, Inflammation, Food, Mortality, Nitric oxide, Shock (mechanics), Survival, Therapy, FDA, MTEC, NO, Food and Drug Administration, Bio, Blood pressure, Death, Kidney, Pharmaceutical industry

Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and hemorrhagic shock, announced the successful completion of its Phase IIa clinical trial of VBI-S in septic shock patients with severe hypovolemia.

Key Points: 
  • Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and hemorrhagic shock, announced the successful completion of its Phase IIa clinical trial of VBI-S in septic shock patients with severe hypovolemia.
  • Severe septic shock patients experience a drastic drop in blood pressure that is associated with multiple organ failure causing patient death.
  • While conventional fluids are effective for treating absolute hypovolemia, they are ineffective for treating relative hypovolemia, which is caused by excessive production of nitric oxide (NO) in septic shock.
  • In the VBI-S Phase IIa trial, reversal of relative hypovolemia led to an increase in blood pressure and improvement of organ function.

Tonix Pharmaceuticals Announces Acquisition of Preclinical Infectious Disease Portfolio from Healion Bio, Inc.

Retrieved on: 
Thursday, February 2, 2023
Research, Food, USAMRIID, Infection, Plasma protein binding, United States Army Medical Research Institute of Infectious Diseases, Center for Global Infectious Disease Research, Tonix Pharmaceuticals, Peginterferon alfa-2a, Viral hepatitis, Maraviroc, Immune system, HIV, Jeju Free International City Development Center, Drug development, Tocilizumab, Viral load, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Severe acute respiratory syndrome coronavirus 2, Tissue, CCR5, RDC, Vaccine, Paul Healion

CHATHAM, N.J., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced an agreement whereby Tonix has acquired all of the assets of Healion Bio, Inc. (Healion) including its entire portfolio of next-generation antiviral technology assets. Healion’s drug portfolio includes a class of broad-spectrum small molecule oral antiviral drug candidates with a novel host-directed mechanism of action. Host-directed antivirals modulate human cells and tissues and are different from direct-acting antivirals which inhibit virus proteins and processes. Tonix’s TNX-3900, formerly known as HB-121, are cathepsin protease inhibitors, some of which have strong activity in vitro against SARS-CoV-2.

Key Points: 
  • Healion’s drug portfolio includes a class of broad-spectrum small molecule oral antiviral drug candidates with a novel host-directed mechanism of action.
  • Host-directed antivirals modulate human cells and tissues and are different from direct-acting antivirals which inhibit virus proteins and processes.
  • Tonix’s TNX-3900, formerly known as HB-121, are cathepsin protease inhibitors, some of which have strong activity in vitro against SARS-CoV-2.
  • On behalf of the talented scientific team that I direct at our 48,000 square-foot cutting-edge infectious disease research facility in Frederick, Md., I am pleased to add this technology to the therapeutic development programs underway.”

New Study Shows Abbott's Blood Test for Concussion Could Predict Outcomes from Brain Injury and Inform Treatment Interventions

Retrieved on: 
Thursday, August 11, 2022
Knowledge, FDA, Death, Biomarker, The Lancet, NYSE, United States Department of Defense, United States Army Medical Research and Development Command, Ubiquitin, Neuron, Brain, CT, Transformative research, Disability, Research, Life, Blood, Probability, Plasma, Ubiquitin carboxy-terminal hydrolase L1, U.S. Department of Defense Strategy for Operating in Cyberspace, Patient, Prognosis, Twitter, Glial fibrillary acidic protein, National Health and Nutrition Examination Survey, GFAP, Mark (given name), United States Army Medical Materiel Agency, EDTA, University, Aline Miller, Emergency medicine, Head, Protein, United States Army Medical Research Institute of Infectious Diseases, LinkedIn, Neurology, Traumatic brain injury, Medical device, Medical imaging, TBI

Researchers measured levels of Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin carboxy-terminal Hydrolase L1 (UCH-L1) present in blood plasma within 24 hours of injury.

Key Points: 
  • Researchers measured levels of Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin carboxy-terminal Hydrolase L1 (UCH-L1) present in blood plasma within 24 hours of injury.
  • The researchers found that high values of the biomarkers, GFAP and UCH-L1, correlate with death and severe injury.
  • Test results are available approximately 15 minutes after a plasma sample is inserted in the test i-STAT cartridge.
  • More information is available at www.globalpointofcare.abbott/en/product-details/apoc/istat-tbi-plasma.html
    The i-STAT Alinity is an easy-to-use, portable blood analyzer that delivers real-time, lab-quality diagnostic test results.